Lansoprazol Flas Stada

Lansoprazole, the active ingredient in Lansoprazol Flas Stada, is a proton pump inhibitor presented as an unknown strength/oral form for oral use. It treats acid‑related disorders such as gastro‑oesophageal reflux disease, peptic ulcer disease, and is employed in Helicobacter pylori eradication regimens.

GNH USA supplies Lansoprazol Flas Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lansoprazole acts on the gastric proton pump to reduce acid secretion, making it useful for several acid‑related conditions. - Gastro‑oesophageal reflux disease (GERD): relieves heartburn and esophageal irritation by lowering gastric acidity. - Peptic ulcer disease: promotes ulcer healing and prevents recurrence by maintaining a less acidic gastric environment. - Helicobacter pylori eradication: used in combination therapy to increase the effectiveness of antibiotics. - NSAID‑induced ulcer prophylaxis: reduces the risk of ulcer formation in patients taking non‑steroidal anti‑inflammatory drugs.

Lansoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: loose stools, usually transient. - Abdominal pain: discomfort or cramping in the stomach area. - Nausea: feeling of sickness, sometimes with vomiting. - Flatulence: increased gas production. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reactions: rash, swelling, anaphylaxis. - Clostridium difficile infection: severe colitis presenting with watery diarrhoea. - Hepatic enzyme elevation: signs of liver dysfunction. - Hypomagnesemia: low magnesium levels causing muscle weakness or arrhythmia. - Bone fractures: increased risk with long‑term use. - Interstitial nephritis: kidney inflammation presenting with reduced urine output.

Before initiating therapy, consider the following precautions. - Renal function assessment: adjust use in patients with severe renal impairment. - Magnesium monitoring: check serum magnesium during prolonged treatment. - Hepatic impairment: use with caution in moderate to severe liver disease. - Discontinuation strategy: avoid abrupt cessation in patients with severe GERD to prevent rebound acid hypersecretion. - Drug interaction review: evaluate concomitant medications that may affect acid levels or drug metabolism. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Lansoprazole may interact with several medicines; awareness helps prevent reduced efficacy or toxicity.

Major Interactions (Avoid): - Atazanavir: decreased absorption leading to sub‑therapeutic antiviral levels. - Clopidogrel: reduced conversion to active metabolite, diminishing antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer coagulation monitoring. - Digoxin: higher serum concentrations may occur, necessitating dose adjustment. - Ketoconazole: reduced oral absorption due to increased gastric pH.